BSE: KPL · Pharmaceuticals
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Kwality Pharmaceuticals Ltd. is an Indian pharmaceutical company specialising in the manufacture of diverse dosage forms, including tablets, injectables, and liquid orals. The company operates primarily as a manufacturer of pharmaceutical formulations.
The company generates revenue through the large-scale production and sale of pharmaceutical formulations across various therapeutic categories. It serves both domestic and international markets by leveraging its manufacturing capabilities in multiple dosage forms.
Growth is expected to be driven by the expansion of its product portfolio and the increasing demand for affordable pharmaceutical formulations. The company continues to focus on enhancing its manufacturing capacity to cater to broader market requirements.
Unlock AI insights, financials, peers and live data on Kwality Pharmaceuticals Limited and 5,000+ companies — free.
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Kwality Pharmaceuticals LimitedKPL | ₹3,409 Cr | — | — | — | 24.0% | — | — | +253.2% |
Zota Health Care LimitedZOTA | ₹3,922 Cr | -36.05 | 339.89 | 78.9% | 1.9% | -22.7% | -14.6% | -14.6% |
Unichem Laboratories LimitedUNICHEMLAB | ₹3,874 Cr | 15.32 | 16.60 | 8.5% | 11.1% | 9.8% | 11.9% | +9.7% |
SMS Pharmaceuticals LimitedSMSPHARMA | ₹3,676 Cr | 34.92 | 21.91 | 10.2% | 20.3% | 14.4% | 15.5% | +68.3% |
Ind-Swift Laboratories LimitedINDSWFTLAB | ₹3,091 Cr | 52.19 | 23.30 | 113.3% | 17.3% | 4.5% | 5.5% | +248.5% |
Solara Active Pharma Sciences LimitedSOLARA | ₹3,050 Cr | -1030.89 | 18.59 | 15.5% | 13.9% | -0.1% | 6.7% | -4.1% |
As of Mar 2026
Kwality Pharmaceuticals Limited
BSE: KPL · Pharmaceuticals
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Kwality Pharmaceuticals Ltd. is an Indian pharmaceutical company specialising in the manufacture of diverse dosage forms, including tablets, injectables, and liquid orals. The company operates primarily as a manufacturer of pharmaceutical formulations.
The company generates revenue through the large-scale production and sale of pharmaceutical formulations across various therapeutic categories. It serves both domestic and international markets by leveraging its manufacturing capabilities in multiple dosage forms.
Growth is expected to be driven by the expansion of its product portfolio and the increasing demand for affordable pharmaceutical formulations. The company continues to focus on enhancing its manufacturing capacity to cater to broader market requirements.
Unlock AI insights, financials, peers and live data on Kwality Pharmaceuticals Limited and 5,000+ companies — free.
As of Mar 2026